Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (5y) (2014 - 2026)
Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.79% |
| Mar 31, 2026 | 7.69% |
| Dec 31, 2025 | 16.22% |
| Sep 30, 2025 | 5.32% |
| Jun 30, 2025 | 82.51% |
| Mar 31, 2025 | 41.00% |
| Dec 31, 2024 | 15.55% |
| Sep 30, 2024 | -6.47% |
| Jun 30, 2024 | -1.14% |
| Mar 31, 2024 | -50.06% |
| Dec 31, 2023 | 3.73% |
| Sep 30, 2023 | -4.30% |
| Jun 30, 2023 | 33.51% |
| Mar 31, 2023 | 3.36% |
| Dec 31, 2022 | 21.72% |
| Sep 30, 2022 | 7.62% |
| Jun 30, 2022 | 3.62% |
| Mar 31, 2022 | -8.22% |
| Dec 31, 2021 | 14.72% |
| Sep 30, 2021 | -0.77% |